Representative Transactions

A central aspect of Matt’s practice is representing private and public companies through multiple rounds of funding and other significant transactions. In the past five years, Matt has handled more than 125 private financings, including seed, venture and other institutional rounds, accounting for over $2.5 billion in capital raised. Representative recent and ongoing engagements include:

• Abdera Therapeutics, a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals for cancer, in its $142M combined Series A and B financing
• Apeel Sciences, a developer of plant-based coatings to preserve fresh produce and reduce food waste, in its $70M Series C financing and $250M Series E financing
• Arcutis Biotherapeutics, a developer of medical dermatology drugs, in connection with company formation, multiple rounds of financing including $95M Series C cross-over financing and 2020 IPO
• Attovia Therapeutics, a developer of a pipeline of biotherapeutics with an initial focus on immune-mediated diseases, in its $105M Series B financing
• BioAge, a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, in its $170M Series D financing
• Calico, a research and development company focused on the biology of aging, in its initial formation and separation from Google (now Alphabet) and its $2.5B strategic collaboration with Abbvie
• Devoted Health, a next-generation all-in-one health care company, in multiple transactions including its $1.15 billion Series D, $175M Series E, and $112M additional Series E financings
• DICE Therapeutics, a novel drug discovery platform company, in its $204M initial public offering and in its conversion to a limited liability company, multiple rounds of private financing and its strategic collaboration agreements with Sanofi and Genentech
• Elegen, a developer of next-generation DNA synthesis and production, in its $35M Series B financing
• Eyconis, Inc. in connection with their formation and $150M capital raise
• GRAIL, a cancer diagnostics company focused on early detection, in its spin-out from Illumina, $100M Series A financing and blockbuster $1B Series B financing
• Lyra Health, a leading provider of innovative Workforce Mental Health solutions for employers, in its recent $235M Series G, $200M Series F, $187M Series E, $75M Series C, and $45M Series B financings
• PassageBio, a gene therapy drug development company, in connection with company formation and negotiation of foundational license agreement with Penn, $115M Series A financing, $110M Series B financing, and 2020 IPO
• Perceive Bio, a biotech company pioneering novel technologies and therapeutics in ophthalmology, in its $78M Series B financing
• PinkDX, an early-stage company focused on positively impacting the health of women throughout their life journey, in its second close of its previously announced Series A financing, raising an additional $5M and bringing the total raised to $45M
• Sudo Biosciences, a biopharmaceutical company committed to designing and developing precision TYK2 (tyrosine kinase 2) inhibitors, in its $116M Series B financing
• Twin Health, inventor of the Whole Body Digital Twin™ precision health service, in its $50M financing

Matt also advises clients on pivotal transactions, including M&A transactions, IPOs and strategic collaborations. Representative recent examples include:

• BioAge Labs, Inc., a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, in its upsized IPO of $238M
• Castlight Health, a leading healthcare data and navigation company, in its announced $370M agreement to combine with Vera Whole Health, a pioneer in advanced primary care
• CareSignal, developer of deviceless remote patient monitoring technology, in its acquisition by Lightbeam Health Solutions, Inc., a leading end-to-end population health management solution
• Channel Medsystems, a medical device technology company, in its agreement to be acquired by Boston Scientific
• Denali Therapeutics, a drug development company focused on neurodegenerative diseases, in its collaboration and option agreement with F-star, and subsequent $450M acquisition of an F-star affiliated entity pursuant to exercise of the option
• DICE Therapeutics, Inc., a biopharmaceutical company focused on the development of novel oral therapeutic medications to treat chronic diseases in immunology, in its acquisition by Eli Lilly and Company
• Endpoint Health, Inc., a precision-first™ therapeutics company dedicated to addressing urgent needs in immune-driven critical and chronic illnesses, in a global collaboration and licensing agreement with Grifols, a leading global producer of plasma-derived medicines
• Lemonaid Health, Inc., an on-demand platform for accessing medical care and pharmacy services online, in its definitive agreement to be acquired by 23andMe Holding Co. for a purchase price of $400M
• Melinta Therapeutics, a company providing innovative therapies for acute and life-threatening illnesses, in its acquisition of the U.S. rights to TOPROL-XL (metoprolol succinate) and its Authorized Generic (AG) from New American Therapeutics, a pharmaceutical company
• Sutro Biopharma, a protein therapeutics drug development company, in connection with a strategic collaboration and acquisition option agreement with Celgene
• The County of Santa Clara in connection with a pro bono engagement to launch California’s first “pay for success” project, which deployed an innovative funding and care delivery model to address chronic homelessness in Santa Clara County

Matt also frequently negotiates licenses on behalf of clients from leading universities, including Stanford University, the University of California, San Francisco and the University of California, Berkeley.

Representative Clients

• AnaptysBio
• Apeel Sciences
• Attovia Therapeutics
• BioAge Labs
• Calico
• Castlight Health
• Channel Medsystems
• Devoted Health
• DICE Therapeutics
• Earli
• Elegen
• EpiBiologics
• Eyconis
• Federation Bio
• Frazier Healthcare
• G2VP
• GRAIL
• Kleiner Perkins Caufield & Byers
• Koya Medical
• Lemonaid Health
• Lyra Health
• Matrixx Software
• Maze Therapeutics
• Melinta Therapeutics
• Passage Bio
• Perceive Bio
• Sudo Biosciences
• Sutro Biopharma
• Virgin America